Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients

Meinolf Suttorp; Markus Metzler; Frederic Millot; Hiroyuki Shimada; Deepak Bansal; Adalet Meral Günes; Krzysztof Kalwak; Petr Sedlacek; Andre Baruchel; Andrea Biondi; Nobuko Hijiya; Kirk R. Schultz; Martin Schrappe

doi:10.1002/pbc.27431

Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients

Meinolf Suttorp^*, Markus Metzler, Frederic Millot, Hiroyuki Shimada, Deepak Bansal, Adalet Meral Günes, Krzysztof Kalwak, Petr Sedlacek, Andre Baruchel, Andrea Biondi, Nobuko Hijiya, Kirk R. Schultz, Martin Schrappe

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.

Original language	English (US)
Article number	e27431
Journal	Pediatric Blood and Cancer
Volume	65
Issue number	12
DOIs	https://doi.org/10.1002/pbc.27431
State	Published - Dec 2018

Keywords

Ph+ leukemia
generic medication
imatinib inhibitor
pediatric
tyrosine kinase

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.27431

Cite this

Suttorp, M., Metzler, M., Millot, F., Shimada, H., Bansal, D., Günes, A. M., Kalwak, K., Sedlacek, P., Baruchel, A., Biondi, A., Hijiya, N., Schultz, K. R., & Schrappe, M. (2018). Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients. Pediatric Blood and Cancer, 65(12), [e27431]. https://doi.org/10.1002/pbc.27431

@article{65336f3ef5604a7f975ba34223edf611,

title = "Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients",

abstract = "Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.",

keywords = "Ph+ leukemia, generic medication, imatinib inhibitor, pediatric, tyrosine kinase",

author = "Meinolf Suttorp and Markus Metzler and Frederic Millot and Hiroyuki Shimada and Deepak Bansal and G{\"u}nes, {Adalet Meral} and Krzysztof Kalwak and Petr Sedlacek and Andre Baruchel and Andrea Biondi and Nobuko Hijiya and Schultz, {Kirk R.} and Martin Schrappe",

note = "Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",

year = "2018",

month = dec,

doi = "10.1002/pbc.27431",

language = "English (US)",

volume = "65",

journal = "Medical and Pediatric Oncology",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "12",

}

TY - JOUR

T1 - Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients

AU - Suttorp, Meinolf

AU - Metzler, Markus

AU - Millot, Frederic

AU - Shimada, Hiroyuki

AU - Bansal, Deepak

AU - Günes, Adalet Meral

AU - Kalwak, Krzysztof

AU - Sedlacek, Petr

AU - Baruchel, Andre

AU - Biondi, Andrea

AU - Hijiya, Nobuko

AU - Schultz, Kirk R.

AU - Schrappe, Martin

PY - 2018/12

Y1 - 2018/12

N2 - Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.

AB - Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.

KW - Ph+ leukemia

KW - generic medication

KW - imatinib inhibitor

KW - pediatric

KW - tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=85052796606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052796606&partnerID=8YFLogxK

U2 - 10.1002/pbc.27431

DO - 10.1002/pbc.27431

M3 - Article

C2 - 30160364

AN - SCOPUS:85052796606

SN - 1545-5009

VL - 65

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

IS - 12

M1 - e27431

ER -

Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this